France Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the France diabetes devices market size is projected to expand from USD 1.39 billion in 2025 and USD 1.47 billion in 2026 to USD 2.02 billion by 2031, registering a CAGR of 6.56% between 2026 to 2031.

This report is Segmented by Device Type (Glucose Monitoring Devices, Insulin Delivery Devices, and Other Diabetes-Care Devices), Diabetes Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational & Others), End User (Hospitals & Clinics, Specialty Clinics, Home-Care Settings, and More). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

France Diabetes Devices Market Trends and Insights

Mainstream Reimbursement Expansion for CGM Sensors

France approved full reimbursement of Dexcom ONE for 100,000 Type 2 patients on basal insulin in June 2024, opening the first European CGM pathway for non-intensive users. Health-economic studies place the incremental cost-effectiveness ratio within national thresholds, reinforcing payer support. As volumes rise, price-volume clauses lower per-sensor reimbursement, limiting manufacturer margins. Integrated sensor-transmitter ecosystems help offset this pressure by locking users into subscription refill models. The 2025 revision of the EU Medical Device Regulation (MDR) embeds post-market surveillance requirements, so real-world CGM outcomes feed directly into reimbursement renewal.

Rapid Uptake of Tubeless and Patch Insulin Pumps

Insulet introduced Omnipod 5 in June 2024, meeting the demand for a discreet, adhesive-based therapy among lifestyle-conscious Type 1 patients. Real-world surveys of 14,765 users show satisfaction driven by convenience rather than superior glycemic metrics. Grenoble-based Diabeloop secured EUR 15 million in 2024 to speed DBLG1 adoption and prepare the smartphone-native DBLG2, which gained FDA clearance by January 2026. The MiniMed 780G spin-off announced by Medtronic in June 2025 underscores escalating competition as agile software innovators shorten upgrade cycles. Future pump growth depends on algorithmic personalization, patch-format miniaturization, and bundle offers that pair hardware, sensor, and support.

Price-Volume Clauses Squeezing Margins

French price tariffs fall once sales thresholds are crossed, curbing profit despite rising CGM penetration. Dexcom ONE reimbursement illustrates this pinch: higher volumes trigger steeper rebates. Manufacturers introduce premium variants with longer wear or predictive alerts to escape existing caps. The 2025 FreeStyle Libre 3 recall shows how speed-to-market gambits carry quality risk that can magnify financial strain.

Other drivers and restraints analyzed in the detailed report include:

1. Smartphone-Integrated SMBG Ecosystems
2. Rapid GLP-1 Adoption Shifting Device Mix
3. Sensor Cybersecurity and GDPR Compliance Burden

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The French diabetes devices market size remained at 57.23% of the French diabetes devices market share that year. Sensors remain volume leaders, yet their growth trails pumps, as margin pressure from price-volume clauses tempers revenue gains. AID-capable patch pumps underpin the 7.87% CAGR in insulin delivery, helped by Omnipod 5 and DBLG1 rollouts. Self-monitoring glucometers continue to lose ground as CGM reimbursement widens and fingerstick avoidance intensifies.

Second-generation pumps are split between tethered (MiniMed 780G, Tandem Control-IQ) and tubeless (Omnipod 5, Kaleido) designs. Recall-driven sensor shortages can temporarily re-inflate SMBG demand, but a structural shift favors sensors and smart pumps.

Complete Report Scope:

• By Device Category
  • Glucose Monitoring Devices
    • Self-Monitoring Blood Glucose (SMBG) Devices
      • Glucometers
      • Test Strips
      • Lancets
    • Continuous Glucose Monitoring (CGM) Devices
      • Sensors
      • Durables (Receivers & Transmitters)
  • Insulin Delivery Devices
    • Insulin Pens
    • Insulin Pumps
    • Insulin Syringes
    • Jet Injectors
  • Other Diabetes-Care Devices
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational & Others
• By End User
  • Hospitals
  • Specialty Clinics
  • Home Care Settings
  • Other End Users

List of Companies Covered in this Report:

1. Abbott Laboratories
2. Ascensia
3. B. Braun
4. Beckton Dickinson
5. Dexcom
6. Eli Lilly and Company
7. Gan & Lee Pharm
8. Insulet
9. Lepu Medical
10. Lifescan
11. Medtronic
12. MicroPort
13. MicroTech Medical Co.
14. Novo Nordisk
15. Roche
16. Sanofi
17. Senseonics Holdings
18. Sinocare
19. Tandem Diabetes Care
20. Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support